retatrutide and joint pain (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: Retatrutide: Is It The Next

Although studies in animal models have shown that GLP-1R agonists reduce Aaccumulation and tau hyperphosphorylation, few human studies have evaluated these effects

Researchers should follow suitable laboratory handling procedures, contamination-control practices, and applicable safety guidance when working with bacteriostatic solutions

Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs

Using evidence-based practices, physicians can use medications to augment weight-loss in patients who have already started to reduce calories and exercise but are still considered overweight by medical standards